Certain embodiments provide a method for preparing a biochemical product (e.g., phenol, catechol, or muconic acid, or a salt thereof). For example, such methods include contacting a recombinant host having two or more recombinant pathways with a fermentable carbon source and growing the recombinant cell for a time sufficient to synthesize the product. In certain embodiments, each recombinant pathway: 1) is capable of producing the same final biochemical product; 2) comprises at least one gene encoding a polypeptide; 3) is derived from a different endogenous metabolite as its immediate precursor; and 4) converges to the same final product or the same intermediate metabolite.

The present disclosure describes the engineering of microbial cells for fermentative production of 3,4-dihydroxybenzoic acid and provides novel engineered microbial cells and cultures, as well as related 3,4-dihydroxybenzoic acid production methods.

A method of producing para-hydroxybenzoic acid (pHBA) or a derivative thereof includes culturing the recombinant microorganism in a fermentation broth, wherein said recombinant microorganism comprising a genetically engineered pathway expressing at least one nucleic acid sequence encoding a polypeptide selected from: an exogenous chorismate pyruvate lyase of EC 5.4.4.2 or EC 4.1.3.40; an exogenous 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) synthase of EC 4.1.2.15, or EC 2.5.1.54; an exogenous shikimate kinase of EC 2.7.1.71; or an exogenous 3-dehydroquinate dehydratase (DHQ) of EC 4.2.1.10; adding a carbon source to the fermentation broth; and isolating the pHBA from the fermentation broth.

The present disclosure relates to a microorganism for producing a mycosporine-like amino acid, and a method for producing a mycosporine-like amino acid using the microorganism. The microorganism of the present disclosure shows an improved ability for producing a mycosporine-like amino acid and thus can be effectively used in the production of a mycosporine-like amino acid.

Disclosed herein are methods for production of 2-phenylethanol by microbial fermentation of substrates comprising carbon monoxide and/or carbon dioxide and further disclosed are genetically modified microorganisms for use in such methods. Additionally, the processes disclosed herein are improved methods of 2-PE production that alleviate dependence on natural and petrochemical processes.

Provided are compositions and methods for compound discovery. Modified yeast that have their endogenous yeast shikimate pathway disrupted or deleted, and replaced with homologous pathway genes from one or more distinct organisms, are provided and used in assays of test agents. The homologous pathway genes are designed to supplement the disrupted or deleted shikimate pathway genes. The assays are designed to identify whether or not the test agents can interfere with the function of enzymes in the shikimate pathway from organisms that are distinct from the yeast avatar hosts. In embodiments, the disruption/deletion of the yeast endogenous shikimate pathway results in the yeast being incapable of producing chorismic acid.

The present disclosure relates to a microorganism for producing a mycosporine-like amino acid, and a method for producing a mycosporine-like amino acid using the microorganism.

The microorganism of the present disclosure shows an improved ability for producing a mycosporine-like amino acid and thus can be effectively used in the production of a mycosporine-like amino acid.

Certain embodiments provide a method for preparing a biochemical product (e.g., phenol, catechol, or muconic acid, or a salt thereof). For example, such methods include contacting a recombinant host having two or more recombinant pathways with a fermentable carbon source and growing the recombinant cell for a time sufficient to synthesize the product. In certain embodiments, each recombinant pathway: 1) is capable of producing the same final biochemical product; 2) comprises at least one gene encoding a polypeptide; 3) is derived from a different endogenous metabolite as its immediate precursor; and 4) converges to the same final product or the same intermediate metabolite.

Provided herein are fermentation compositions and methods for improved production of vanillin and/or glucovanillin. The compositions and methods described herein provide efficient routes for the production of vanillin and/or glucovanillin and any compound that can be synthesized or biosynthesized from either or both.

Provided herein are glycan engineered SARS-CoV-2 RBD polypeptides, fusion polypeptides comprising thereof, and immunogenic compositions comprising thereof. Also provided are methods of administering the RBD polypeptide, fusion polypeptide or immunogenic composition to a subject to elicit an immune response. Also provided are polynucleotides encoding the fusion polypeptide, and methods of administering a composition comprising the polynucleotide to a subject to elicit an immune response. In some embodiments, the polynucleotide is an RNA comprising modified ribonucleotides.